Lilly to Acquire Dice for $2.4B: Boosting Immunology Pipeline

Overview Eli Lilly has made headlines with its acquisition of DICE Therapeutics for a striking $2.4 billion. This deal is set to enhance Lilly’s immunology pipeline, primarily through two advanced clinical-stage programs that are focused on oral interleukin-17 (IL-17) inhibitors. One of the key highlights...

Sanofi Pfizer and Various Manufacturers: Hydroxychloroquine, Chloroquine, and Azithromycin in Pharmaceutical Research

Overview Antiviral Candidates and Their Uses The research into antiviral treatments for COVID-19 has explored several existing drugs. These include Plaquenil® (hydroxychloroquine sulfate) combined with Zithromax® (azithromycin), and monotherapies such as chloroquine phosphate, chloroquine hydrochloride, and azithromycin in its various forms. Hydroxychloroquine and chloroquine are...

Base Editors and Prime Editors: Clinical Promise Unfolds

Overview Base editing and prime editing have transformed the field of genome editing. David Liu’s team introduced base editing in 2016, offering a method to convert one DNA base to another without breaking the DNA strand. This technique minimizes the risk of off-target mutations, making...